Skip to content

Search

Trans Tasman action to fast track rheumatic fever vaccine

Prime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.

Infectious Disease & Vaccination Public Seminar

Hear the facts about vaccination and infectious disease from some of Australia's leading experts: Professor Jonathan Carapetis, Dr Peter Richmond

State Immunisation Strategy Released

The State Government has launched a new strategy for improving immunisation rates among WA children, to prevent outbreaks of diseases like measles & meningitis

WANTED: 'Flu Busters

Hundreds of healthy volunteers are needed in Perth to test the effectiveness of a current 'flu vaccine.

New vaccine may provide broader protection against cervical cancer

Just under 150 Perth women have contributed to major international research at the Telethon Institute for Child Health Research.

Perth researchers to trial bird flu vaccine

Perth researchers have begun a trial to test the effectiveness of a new vaccine to protect against the potentially deadly bird flu.

New study examines vacccine to prevent cervical cancer

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

Rheumatic heart disease remains a major killer in Oceania region

A new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants

Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.